Mineralys Therapeutics Stock (NASDAQ:MLYS)
Previous Close
$10.01
52W Range
$8.24 - $15.25
50D Avg
$10.48
200D Avg
$12.06
Market Cap
$530.50M
Avg Vol (3M)
$272.98K
Beta
1.51
Div Yield
-
MLYS Company Profile
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.